ストックスクリーナーアプリを入手
2.975
0.50%
-0.025
前日終値:
$3.00
開ける：
$3
24時間の取引高:
389.02K
Relative Volume:
1.03
時価総額：
$232.82M
収益：
$351.37M
当期純損益:
$-174.01M
株価収益率:
-1.4372
EPS:
-2.07
ネットキャッシュフロー:
$-126.94M
1週間 パフォーマンス:
+0.84%
1か月 パフォーマンス:
-9.27%
6か月 パフォーマンス:
+6.23%
1年 パフォーマンス:
-8.15%
1日の値動き範囲:
$2.925
$3.035
1週間の範囲:
$2.92
$3.18
52週間の値動き範囲:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
AVIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
2.98 | 234.38M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.01 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.11 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.15 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.89 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.22 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada
Atea Pharma (NASDAQ: AVIR) hosts Evercore fireside chat Dec. 3 at 10:00 a.m. ET - Stock Titan
Is a relief rally coming for Atea Pharmaceuticals Inc. holdersProduct Launch & High Return Trade Opportunity Guides - newser.com
How Atea Pharmaceuticals Inc. stock performs in rate cut cyclesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
William Blair Has Negative Outlook of AVIR FY2025 Earnings - Defense World
Atea Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Live market analysis of Atea Pharmaceuticals Inc.CEO Change & AI Enhanced Market Trend Forecasts - newser.com
Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism - MSN
Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
What drives Atea Pharmaceuticals Inc stock pricePrice Support Zones & High Return Wealth Building - earlytimes.in
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AVIR) 2025-11-14 - Seeking Alpha
Atea Pharmaceuticals Advances Antiviral Programs with New Data - TipRanks
Atea Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss By Investing.com - Investing.com Nigeria
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss - Investing.com
Atea Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report | AVIR SEC FilingForm 10-Q - Stock Titan
Atea Pharmaceuticals, Inc. (AVIR) Q3 FY2025 earnings call transcript - Yahoo Finance
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Atea Pharmaceuticals : Q3 Slides November 12 2025 FINAL - MarketScreener
[8-K] Atea Pharmaceuticals, Inc. Reports Material Event | AVIR SEC FilingForm 8-K - Stock Titan
Atea (Nasdaq: AVIR) says HCV Phase 3 on track; C-BEYOND topline results mid-2026 - Stock Titan
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
Atea Pharmaceuticals Inc (AVIR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):